LearnGlossaryMarketStocksSuperinvestorsSign in

LUNG

Pulmonx Corporation

Healthcare · $81M market cap

Verdict

We can't put a fair value on LUNG right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-28.4% a year✗
Sales growth22.3% a year✓
Free cash flow growth—?
Return on invested capital-42.6%✗

Follow LUNG

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 14 sales worth $177K. Why purchases matter

Sales

Rose Geoffrey Beran

Chief Commercial Officer · 2026-09-01

Sold

$4K

Rose Geoffrey Beran

Chief Commercial Officer · 2026-09-01

Sold

$3K

Rose Geoffrey Beran

Chief Commercial Officer · 2026-09-01

Sold

$5K

Rose Geoffrey Beran

Chief Commercial Officer · 2026-09-01

Sold

$5K

Lehman David Aaron

General Counsel · 2026-09-01

Sold

$11K

Show all 14 sales

Lehman David Aaron

General Counsel · 2026-09-01

Sold

$8K

Lehman David Aaron

General Counsel · 2026-09-01

Sold

$5K

Lehman David Aaron

General Counsel · 2026-09-01

Sold

$9K

Radhakrishnan Srikanth

Chief Science & Techn. Officer · 2026-09-01

Sold

$13K

Radhakrishnan Srikanth

Chief Science & Techn. Officer · 2026-09-01

Sold

$8K

Radhakrishnan Srikanth

Chief Science & Techn. Officer · 2026-09-01

Sold

$5K

Radhakrishnan Srikanth

Chief Science & Techn. Officer · 2026-09-01

Sold

$6K

French Glendon E. III

President and CEO · 2026-09-01

Sold

$85K

French Glendon E. III

President and CEO · 2026-09-01

Sold

$9K

About Pulmonx Corporation

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works